Educational CyberPlayGround, Inc
NetHappenings Newsletter
sign up/unsubscribe anytime here
https://cyberplayground.com
follow @cyberplayground @nethappenings
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
It’s on the way to the FDA now for approval.
Pfizer and BioNTech today provided an update on their COVID-19 vaccine. They now report 95% efficacy for their vaccine candidate, drawing on the final analysis of a 43,000-person study. Efficacy only drops to 94% in people over 65 years of age.
Science’s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.
Not to be outdone by a rival with a similar product, Pfizer and BioNTech today provided an update on the previously announced success of their COVID-19 vaccine. The U.S. pharma giant and its German biotech partner now report 95% efficacy for their vaccine candidate, drawing on the final analysis of a 43,000-person study. And don’t worry about the elderly not responding to the vaccine; the efficacy only drops to 94% in people over 65 years of age, the companies said in a press release.
The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race
Amazon launches Amazon Pharmacy for prescription medicine delivery